308 related articles for article (PubMed ID: 17990351)
21. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
23. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab: a review of its use in metastatic colorectal cancer.
McCormack PL; Keam SJ
Drugs; 2008; 68(4):487-506. PubMed ID: 18318567
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
26. Targeting Angiogenesis in Colorectal Carcinoma.
Lopez A; Harada K; Vasilakopoulou M; Shanbhag N; Ajani JA
Drugs; 2019 Jan; 79(1):63-74. PubMed ID: 30617958
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab in the treatment of colorectal cancer.
Cilley JC; Barfi K; Benson AB; Mulcahy MF
Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
[TBL] [Abstract][Full Text] [Related]
29. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
30. The future development of bevacizumab in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
[TBL] [Abstract][Full Text] [Related]
31. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
Cartwright TH
Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer.
Chu E
Clin Colorectal Cancer; 2004 May; 4(1):16. PubMed ID: 15207014
[No Abstract] [Full Text] [Related]
33. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
Fakih M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Hurwitz H; Kabbinavar F
Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
[TBL] [Abstract][Full Text] [Related]
35. Drug insight: VEGF as a therapeutic target for breast cancer.
Schneider BP; Sledge GW
Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
[TBL] [Abstract][Full Text] [Related]
36. Biological therapy update in colorectal cancer.
Sorscher SM
Expert Opin Biol Ther; 2007 Apr; 7(4):509-19. PubMed ID: 17373902
[TBL] [Abstract][Full Text] [Related]
37. Anti-angiogenic treatment of gastrointestinal malignancies.
Salmon JS; Lockhart AC; Berlin J
Cancer Invest; 2005; 23(8):712-26. PubMed ID: 16377590
[TBL] [Abstract][Full Text] [Related]
38. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Vanhoefer U
Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
[TBL] [Abstract][Full Text] [Related]
39. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
Giampieri R; Caporale M; Pietrantonio F; De Braud F; Negri FV; Giuliani F; Pusceddu V; Demurtas L; Restivo A; Fontanella C; Aprile G; Cascinu S; Scartozzi M
Crit Rev Oncol Hematol; 2016 Apr; 100():99-106. PubMed ID: 26907512
[TBL] [Abstract][Full Text] [Related]
40. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]